| Vaccination Program for Commercial Layers |
| Age |
Vaccine |
Route |
Type |
| 1 day |
Marek’s disease |
SC |
Turkey herpesvirusand SB-1 |
| 14 –21 days |
Newcastle/infectious bronchitis |
Water |
B1/Mass |
| 14–21 days |
Infectious bursal disease |
Water |
Intermediate |
| 5 wk |
Newcastle/infectious bronchitis |
Water or coarse spray |
B1 or LaSota/Mass |
| 8–10 wk |
Newcastle/infectious bronchitis |
Water or coarse spray |
B1 or LaSota/Mass |
| 10–12 wk |
Encephalomyelitis |
Wing web |
Live, chick-embryo Origin |
| 10–12 wk |
Fowlpox |
Wing web |
Modified live |
| 10–12 wk |
Laryngotracheitis |
Intraocular |
Modified live |
| 10–14 wk |
Mycoplasma gallisepticumb |
Intraocular or spray |
Mild live strain |
| 12–14 wk |
Newcastle/infectious bronchitis |
Water or aerosol |
B1 or LaSota/Mass |
| 16–18 wk |
Newcastle/infectious bronchitis |
Water or aerosol |
B1 or LaSota/Mass |
| Every 60–90 days or 18 wk |
Newcastle/infectious bronchitis |
Parenteral |
Inactivated |
| This is an example of a vaccination program. Individual programs are highly variable and reflect local conditions, disease prevalence, severity of challenge, and individual preferences. |
